The most remarkable immunobiological finding of our study was that, paradoxically, when combined with anti-PD1, CXCR2 inhibition leads to an increase in tumour neutrophils and a selective reprogramming of the TAN neutrotime, with no evidence for a similar systemic effect on circulating neutrophils. Here, CXCR2 is linked to neoplasm.